All In Biotech

Investigational drug · Phase 3

rilparencel

Also called: Renal Autologous Cell Therapy, REACT

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes Mellitus, Chronic Kidney Diseases, Type 1 Diabetes Mellitus.

Phase 3

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

3

Any phase or sponsor naming "rilparencel"

First trial start

2021

Jul 27, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "rilparencel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Type 2 Diabetes Mellitus
  • Chronic Kidney Diseases
  • Type 1 Diabetes Mellitus

Approved drugs for the same conditions: Type 2 diabetes · Type 1 diabetes · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "rilparencel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 65,071 on PubMed

Also in development for Type 2 Diabetes Mellitus

  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • ElecoglipronPhase 39 trials

    AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight

  • LenbelintideAZD6234Phase 39 trials

    AstraZeneca · Obesity or Overweight, Obesity, Overweight

  • ASC30 A1ASC30Phase 35 trials

    Ascletis Pharma (China) Co., Limited · Chronic Weight Management, Obesity, Overweight

  • SHR-3167Phase 35 trials

    Jiangsu HengRui Medicine Co., Ltd. · Diabetes Mellitus, Type 2, Type 2 Diabetes, Type 2 Diabetes Mellitus

  • HTD1801Berberine UrsodeoxycholatePhase 34 trials

    Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes

  • DA-302168SPhase 33 trials

    Chendu DIAO Pharmaceutical Group CO., LTD. · Overweight and Obesity, Type 2 Diabetes Mellitus

  • TG103Phase 33 trials

    CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Type 2 Diabetes Mellitus, Overweight or Obesity

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.